

side

result set

DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<u>L6</u>	L5 and (diagnos\$ or detect\$)same (disease\$ or disorder\$ or patholog\$ or condition\$)	40	<u>L6</u>
<u>L5</u>	(L2 or L3 or L4) and psgl\$	45	<u>L5</u>
<u>L4</u>	moore.in.	28204	<u>L4</u>
<u>L3</u>	mcever.in.	123	<u>L3</u>
<u>L2</u>	cummings.in.	3893	<u>L2</u>
<u>L1</u>	(diagnos\$ or detect\$)same (disease\$ or disorder\$ or patholog\$)same (psgl\$)	25	<u>L1</u>

END OF SEARCH HISTORY

egin 5,73,155,399

27nov06 13:40:16 User208760 Session D2800.2

\$0.00 0.102 DialUnits File410

\$0.00 Estimated cost File410

\$0.02 TELNET

\$0.02 Estimated cost this search

\$0.44 Estimated total session cost 0.221 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2006/Nov W3

(c) 2006 The Thomson Corporation

File 73:EMBASE 1974-2006/Nov 27

(c) 2006 Elsevier B.V.

File 155:MEDLINE(R) 1950-2006/Nov 21

(c) format only 2006 Dialog

*File 155: The file has resumed updating with UD20061120,
with RT=IN DATA REVIEW and RT=IN PROCESS records.

File 399:CA SEARCH(R) 1967-2006/UD=14523

(c) 2006 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set Items Description

? cummings richard ?

>>>Invalid parameter: UMMINGS

? e au=cummings richard ?

Ref	Items	Index-term
E1	16	AU=CUMMINGS RICHARD
E2	0	*AU=CUMMINGS RICHARD ?
E3	201	AU=CUMMINGS RICHARD D
E4	2	AU=CUMMINGS RICHARD DALE
E5	23	AU=CUMMINGS RICHARD T
E6	3	AU=CUMMINGS RICK
E7	2	AU=CUMMINGS ROB I
E8	2	AU=CUMMINGS ROBERT
E9	1	AU=CUMMINGS ROBERT F
E10	2	AU=CUMMINGS ROBERT J
E11	1	AU=CUMMINGS ROBERT S
E12	1	AU=CUMMINGS ROBERT S JR

Enter P or PAGE for more

? s e1-e5

16	AU=CUMMINGS RICHARD
0	AU=CUMMINGS RICHARD ?
201	AU=CUMMINGS RICHARD D
2	AU=CUMMINGS RICHARD DALE
23	AU=CUMMINGS RICHARD T

S1 242 E1-E5

? e au=moore kevin ?

Ref	Items	Index-term
E1	1	AU=MOORE KERRINA
E2	84	AU=MOORE KEVIN
E3	0	*AU=MOORE KEVIN ?
E4	3	AU=MOORE KEVIN B
E5	3	AU=MOORE KEVIN C
E6	2	AU=MOORE KEVIN E
E7	1	AU=MOORE KEVIN J
E8	45	AU=MOORE KEVIN L
E9	10	AU=MOORE KEVIN M

E10 47 AU=MOORE KEVIN P
 E11 13 AU=MOORE KEVIN R
 E12 59 AU=MOORE KEVIN W

Enter P or PAGE for more

? s e2,d8

>>>Invalid term in list: D8

? s e2,e8

84 AU=MOORE KEVIN
 45 AU=MOORE KEVIN L
 S2 129 E2,E8

? e au=mcever rodger ?

Ref	Items	Index-term
E1	1	AU=MCEVER R.R.
E2	3	AU=MCEVER RODGER
E3	0	*AU=MCEVER RODGER ?
E4	162	AU=MCEVER RODGER P
E5	3	AU=MCEVER ROGER P
E6	2	AU=MCEVER V W
E7	1	AU=MCEVER V W III
E8	1	AU=MCEVER, JIMMIE GREENE, III
E9	1	AU=MCEVER, L. F.
E10	4	AU=MCEVER, R. P.
E11	1	AU=MCEVER, RODGER
E12	157	AU=MCEVER, RODGER P.

Enter P or PAGE for more

? s e1-12

>>>Term "12" in invalid position

? s e1-e12

1 AU=MCEVER R.R.
 3 AU=MCEVER RODGER
 0 AU=MCEVER RODGER ?
 162 AU=MCEVER RODGER P
 3 AU=MCEVER ROGER P
 2 AU=MCEVER V W
 1 AU=MCEVER V W III
 1 AU=MCEVER, JIMMIE GREENE, III
 1 AU=MCEVER, L. F.
 4 AU=MCEVER, R. P.
 1 AU=MCEVER, RODGER
 157 AU=MCEVER, RODGER P.

S3 336 E1-E12

? s (s1 or s2 or s3) and (psgl\$)

242 S1
 129 S2
 336 S3
 0 PSGL\$

S4 0 (S1 OR S2 OR S3) AND (PSGL\$)

? s (s1 or s2 or s3) and (psgl?)

242 S1
 129 S2
 336 S3
 1861 PSGL?

S5 125 (S1 OR S2 OR S3) AND (PSGL?)

? rd s5

S6 70 RD S5 (unique items)

? s s6 and (diagnos? or detect?) (20n) (diseas? or disorder? or condition?)

Processing

Processing

70 S6

5873949 DIAGNOS?
 3340223 DETECT?
 9871459 DISEAS?
 2375630 DISORDER?
 2748881 CONDITION?
 1866322 (DIAGNOS? OR DETECT?) (20N) ((DISEAS? OR DISORDER?) OR
 CONDITION?)
 S7 0 S6 AND (DIAGNOS? OR DETECT?) (20N) (DISEAS? OR DISORDER? OR
 CONDITION?)
 ? s s6 and (diagnos? or detect?)and(diseas? or disorder? or condition?)
 Processing
 Processing
 70 S6
 5873949 DIAGNOS?
 3340223 DETECT?
 9871459 DISEAS?
 2375630 DISORDER?
 2748881 CONDITION?
 S8 2 S6 AND (DIAGNOS? OR DETECT?)AND(DISEAS? OR DISORDER? OR
 CONDITION?)
 ? rd s8
 S9 2 RD S8 (unique items)
 ? t s9/3/all

9/3/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0013535972 BIOSIS NO.: 200200129483
 P-selectin glycoprotein ligand-1-deficient mice have residual leukocyte
 rolling on P-selectin and impaired leukocyte tethering to E-selectin
 under flow
 AUTHOR: Xia Lijun (Reprint); Sperandio Markus; Yago Tadayuki (Reprint);
 McDaniel Michael; Cummings Richard D; Pearson-White Sonia; Ley Klaus;
 McEver Rodger P (Reprint)
 AUTHOR ADDRESS: Department of Medicine, Warren Medical Institute,
 University of Oklahoma HSC, Oklahoma City, OK, USA**USA
 JOURNAL: Blood 98 (11 Part 1): p13a November 16, 2001 2001
 MEDIUM: print
 CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of
 Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
 SPONSOR: American Society of Hematology
 ISSN: 0006-4971
 DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
 RECORD TYPE: Abstract
 LANGUAGE: English

9/3/2 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0012183312 BIOSIS NO.: 199900442972
 A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte
 adhesion to P-selectin
 AUTHOR: Leppanen Anne; Mehta Padmaja; Ouyang Ying-Bin; Ju Tongzhong; Helin
 Jari; Moore Kevin L; van Die Irma; Canfield William M; McEver
 Rodger P; Cummings Richard D (Reprint)
 AUTHOR ADDRESS: Dept. of Biochemistry and Molecular Biology, University of
 Oklahoma Health Sciences Center, 975 N.E. 10th St., BRC417, Oklahoma
 City, OK, 73104, USA**USA
 JOURNAL: Journal of Biological Chemistry 274 (35): p24838-24848 Aug. 27,

1999 1999
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
? t s9/7/all

9/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013535972 BIOSIS NO.: 200200129483
P-selectin glycoprotein ligand-1-deficient mice have residual leukocyte rolling on P-selectin and impaired leukocyte tethering to E-selectin under flow
AUTHOR: Xia Lijun (Reprint); Sperandio Markus; Yago Tadayuki (Reprint); McDaniel Michael; Cummings Richard D; Pearson-White Sonia; Ley Klaus; McEver Rodger P (Reprint)
AUTHOR ADDRESS: Department of Medicine, Warren Medical Institute, University of Oklahoma HSC, Oklahoma City, OK, USA**USA
JOURNAL: Blood 98 (11 Part 1): p13a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: P-selectin glycoprotein ligand-1-deficient (PSGL-1-/-) mice prepared by gene targeting were healthy but had moderately elevated total blood leukocytes. Fluid-phase P-selectin did not detectably bind to PSGL-1-/- neutrophils, and only a few PSGL-1-/- leukocytes rolled on even high densities of P-selectin in vitro. Small but significant numbers of PSGL-1-/- leukocytes rolled on P-selectin expressed on venules of trauma- or TNF-a-stimulated cremaster muscle in vivo; these cells rolled significantly faster than PSGL-1+/+ leukocytes. Fluid-phase E-selectin bound to approx 70% fewer sites on PSGL-1-/- than PSGL-1+/+ neutrophils. Compared to PSGL-1+/+ leukocytes, significantly fewer PSGL-1-/- leukocytes rolled on E-selectin in vitro, because their initial tethering to E-selectin was impaired. Those cells that did tether rolled with the same shear resistance and velocities as PSGL-1+/+ leukocytes. Compared to PSGL-1+/+ mice, significantly fewer PSGL-1-/- leukocytes rolled on E-selectin in TNF-a-treated venules in which P-selectin function was blocked by a mAb. The residual PSGL-1-/- leukocytes that tethered rolled with equivalent slow velocities as PSGL-1+/+ leukocytes. These results demonstrate that PSGL-1 is the dominant but not the sole leukocyte ligand for P-selectin and that PSGL-1 is important for leukocyte tethering to E-selectin under physiological flow conditions.

9/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012183312 BIOSIS NO.: 199900442972
A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin
AUTHOR: Leppanen Anne; Mehta Padmaja; Ouyang Ying-Bin; Ju Tongzhong; Helin Jari; Moore Kevin L; van Die Irma; Canfield William M; McEver

Rodger P; Cummings Richard D (Reprint)
AUTHOR ADDRESS: Dept. of Biochemistry and Molecular Biology, University of
Oklahoma Health Sciences Center, 975 N.E. 10th St., BRC417, Oklahoma
City, OK, 73104, USA**USA
JOURNAL: Journal of Biological Chemistry 274 (35): p24838-24848 Aug. 27,
1999 1999
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: P-selectin glycoprotein ligand-1 (PSGL-1) is a dimeric
membrane mucin on leukocytes that binds selectins. The molecular features
of ***PSGL*** -1 that determine this high affinity binding are unclear.
Here we demonstrate the in vitro synthesis of a novel glycosulfopeptide
(GSP-6) modeled after the extreme N terminus of PSGL-1, which has
been predicted to be important for P-selectin binding. GSP-6 contains
three tyrosine sulfate (TyrSO3) residues and a monosialylated, core
2-based O-glycan with a sialyl Lewis X (C2-O-sLex) motif at a specific
Thr residue. GSP-6 binds tightly to immobilized P-selectin, whereas
glycopeptides lacking either TyrSO3 or C2-O-sLex do not detectably
bind. Remarkably, an isomeric glycosulfopeptide to GSP-6, termed GSP-6',
which contains sLex on an extended core 1-based O-glycan, does not bind
immobilized P-selectin. Equilibrium gel filtration analysis revealed that
GSP-6 binds to soluble P-selectin with a Kd of approx 350 nM. GSP-6 (<5
muM) substantially inhibits neutrophil adhesion to P-selectin in vitro,
whereas free sLex (5 mM) only slightly inhibits adhesion. In contrast to
the inherent heterogeneity of post-translational modifications of
recombinant proteins, glycosulfopeptides permit the placement of sulfate
groups and glycans of precise structure at defined positions on a
polypeptide. This approach should expedite the probing of
structure-function relationships in sulfated and glycosylated proteins,
and may facilitate development of novel drugs to treat inflammatory
diseases involving P-selectin-mediated leukocyte adhesion.
? s (psgl?) (20n) (diagnos? or detect?) (20n) (diseas? or disorder? or condition?)

Processing
Processing

1861 PSGL?
5873949 DIAGNOS?
3340223 DETECT?
9871459 DISEAS?
2375630 DISORDER?
2748881 CONDITION?
S10 24 (PSGL?) (20N) (DIAGNOS? OR DETECT?) (20N) (DISEAS? OR
DISORDER? OR CONDITION?)

? rd s10

S11 14 RD S10 (unique items)

? t s11/3/all

11/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0016086159 BIOSIS NO.: 200600431554

Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic
murine ileitis

AUTHOR: Rivera-Nieves Jess (Reprint); Burcin Tracy L; Olson Timothy S;
Morris Margaret A; McDuffie Marcia; Cominelli Fabio; Ley Klaus

AUTHOR ADDRESS: Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence,
Charlottesville, VA 22908 USA**USA

AUTHOR E-MAIL ADDRESS: jr3u@virginia.edu

JOURNAL: Journal of Experimental Medicine 203 (4): p907-917 APR 17 2006
2006.
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013396971 BIOSIS NO.: 200100568810
Tonsillar B cells do not express PSGL-1, but a significant fraction
displays the cutaneous lymphocyte antigen and exhibits effective E- and
P-selectin ligand activity
AUTHOR: Armerding Dieter (Reprint); Fuhlbrigge Robert C; Kieffer J David;
Kupper Thomas S
AUTHOR ADDRESS: Donaustrasse 73, A-3421, Hofelein an der Donau, Austria**
Austria
JOURNAL: International Archives of Allergy and Immunology 126 (1): p78-90
September, 2001 2001
MEDIUM: print
ISSN: 1018-2438
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013273769 BIOSIS NO.: 200100445608
Regulation of P-selectin binding to the neutrophil P-selectin
counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase
and cathepsin G
AUTHOR: Gardiner Elizabeth E; De Luca Mariagrazia; McNally Tracy; Michelson
Alan D; Andrews Robert K; Berndt Michael C (Reprint)
AUTHOR ADDRESS: Baker Medical Research Institute, St Kilda Rd, Central,
Melbourne, VIC, Australia**Australia
JOURNAL: Blood 98 (5): p1440-1447 September 1, 2001 2001
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013257113 BIOSIS NO.: 200100428952
Expression and function of P-selectin glycoprotein ligand 1 (CD162) on
human basophils
AUTHOR: Taylor Marcia L; Brummet Mary E; Hudson Sherry A; Miura Katsu;
Bochner Bruce S (Reprint)
AUTHOR ADDRESS: Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bay
View Circle, Baltimore, MD, 21224-6801, USA**USA
JOURNAL: Journal of Allergy and Clinical Immunology 106 (5): p918-924
November, 2000 2000

MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10823146 EMBASE No: 2000305388
Activation of human leukocytes reduces surface P-selectin glycoprotein
ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro
Davenpeck K.L.; Brummet M.E.; Hudson S.A.; Mayer R.J.; Bochner B.S.
Dr. B.S. Bochner, Johns Hopkins Asthma/Allergy Center, 5501 Hopkins
Bayview Circle, Baltimore, MD 21224 United States
AUTHOR EMAIL: bbochner@welch.jhu.edu
Journal of Immunology (J. IMMUNOL.) (United States) 01 SEP 2000, 165/5
(2764-2772)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 39

11/3/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142353888 CA: 142(19)353888h PATENT
Antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb
and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and
inflammation
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther;
Hagay, Yocheved; Ben-levy, Rachel; Nisgav, Yael; Kanfi, Yariv
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050069955 A1 DATE: 20050331
APPLICATION: US 2004880922 (20040630) *US 2003PV484061 (20030630)
PAGES: 74 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007100; G01N-033/53A; C07K-016/18B

11/3/7 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142349113 CA: 142(19)349113j (CORRECTION OF 142(9)148820p) PATENT
Anti-PSGL-1 antibodies, and diagnostic and therapeutic use
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel;
Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton,
Esther; Kanfi, Yariv; Ben-Levy, Rachel
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200505455 A2 DATE: 20050120
APPLICATION: WO 2004US21099 (20040630) *US 2003610840 (20030630)
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;

GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

11/3/8 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142259973 CA: 142(14)259973k PATENT
Antibodies specific to human interleukin-22 for diagnosis and treatment
of inflammatory and immune or autoimmune diseases
INVENTOR(AUTHOR): Li, Jing; Tan, Xiang-yang; Tomkinson, Kathleen N.;
Pittman, Debra D.; Veldman, Geertruida M.; Fouser, Lynette
LOCATION: USA
ASSIGNEE: Genetics Institute, LLC
PATENT: U.S. Pat. Appl. Publ. ; US 20050042220 A1 DATE: 20050224
APPLICATION: US 2004873972 (20040622) *US 2001PV270823 (20010223) *US
2001PV281353 (20010403) *US 200284298 (20020225) *US 2003PV480652
(20030623)
PAGES: 59 pp., Cont.-in-part of U.S. Ser. No. 84,298. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424145100; C07K-016/24A; A61K-039/395B

11/3/9 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142196523 CA: 142(11)196523r PATENT
Antibodies bind to sulfated epitopes involving cell rolling, metastasis,
inflammation, viral entry and autoimmune disease for diagnosis, prognosis
and therapy
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther;
Hagay, Yocheved; Ben-Levy, Rachel; Nisgav, Yael; Szrajber, Tali; Kanfi,
Yariv
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200510153 A2 DATE: 20050203
APPLICATION: WO 2004US21002 (20040630) *US 2003611238 (20030630)
PAGES: 134 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

11/3/10 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

141365149 CA: 141(22)365149k PATENT
Anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
therapy of cancer, metastasis, autoimmune disease and inflammation
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;
Szanton, Esther; Hagai, Yocheved; Mar-Chaim, Hagit Hoch
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040208877 A1 DATE: 20041021
APPLICATION: US 611588 (20030630) *US PV393491 (20020701)
PAGES: 49 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424146100; C12Q-001/68A; A61K-039/395B; C07K-016/40B

11/3/11 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for
diagnosis, prognosis and treatment of cancer, inflammation, infection,
autoimmune disease, metastasis and leukemia
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;
Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108
APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/12 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140092576 CA: 140(7)92576c PATENT
Antibodies specific to epitopes involving cell rolling, metastasis and
inflammation for diagnosis and treatment of cancer, metastasis, leukemia,
autoimmune disease and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101
APPLICATION: US 32423 (20011231) *US PV258948 (20001229)
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B;

C07K-014/16B; C07K-007/08B; C07K-007/06B

11/3/13 (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

137108286 CA: 137(8)108286j PATENT
Antibodies and fragments against epitopes present on cancer, metastatic
or leukemia cells and platelets for diagnosis and therapy of tumor,
metastasis, leukemia, autoimmune disease, and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagai, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Kooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: USA
ASSIGNEE: Bio-Technology General Corp.
PATENT: PCT International ; WO 200253700 A2 DATE: 20020711
APPLICATION: WO 2001US49442 (20011231) *US 751181 (20001229) *US PV258948
(20001229)
PAGES: 310 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ;
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

11/3/14 (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

136000640 CA: 136(1)640k PATENT
Methods for diagnosing and treating hemostatic disorders by modulating
P-selectin activity
INVENTOR(AUTHOR): Wagner, Denisa D.; Andre, Patrick; Hartwell, Daqing W.;
Hrachovinova, Ingrid
LOCATION: USA
ASSIGNEE: The Center for Blood Research
PATENT: PCT International ; WO 200189564 A2 DATE: 20011129
APPLICATION: WO 2001US16021 (20010517) *US PV205734 (20000519)
PAGES: 93 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A; A61K-048/00B; A61K-038/17B; A61K-035/14B;
A61P-007/00B; A61P-009/00B; A61P-035/00B; G01N-033/50B; G01N-033/86B;
G01N-033/68B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
? t s11/7/1-5

11/7/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0016086159 BIOSIS NO.: 200600431554

Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis

AUTHOR: Rivera-Nieves Jess (Reprint); Burcin Tracy L; Olson Timothy S;

Morris Margaret A; McDuffie Marcia; Cominelli Fabio; Ley Klaus

AUTHOR ADDRESS: Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA**USA

AUTHOR E-MAIL ADDRESS: jr3u@virginia.edu

JOURNAL: Journal of Experimental Medicine 203 (4): p907-917 APR 17 2006
2006

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The Journal of Experimental Medicine L-selectin ligands might be relevant for inflammatory cell trafficking into the small intestine in a spontaneous model of chronic ileitis (i.e., SAMP1/YitFc mice). Immunoblockade of peripheral node addressin or mucosal addressin cell adhesion molecule 1 failed to ameliorate ileitis, whereas P-selectin glycoprotein ligand 1 (PSGL-1) neutralization attenuated both the adoptively transferred and spontaneous ***disease***. ***PSGL*** -1 was detected in venules of mesenteric lymph node and small intestine by immunohistochemistry and confirmed by real-time reverse transcription polymerase chain reaction and flow cytometry. In addition, reconstitution of wild-type mice with PSGL-1(-/-) bone marrow demonstrated that PSGL-1 messenger RNA and PSGL-1 protein expression remained on endothelium, localized within mesenteric lymph node and small intestine. Endothelial PSGL-1 bound P-selectin-IgG and its blockade or genetic deletion altered the recruitment of lymphocytes to the small intestine, as revealed by intravital microscopy and homing studies. Endothelial expression of PSGL-1 adds a new dimension to the various cellular interactions involved in small intestinal recruitment. Thus, the multiple roles of PSGL-1 may explain why targeting this single adhesion molecule results in attenuation of chronic murine ileitis, a disease previously resistant to antiadhesion molecule strategies.

11/7/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013396971 BIOSIS NO.: 200100568810

Tonsillar B cells do not express PSGL-1, but a significant fraction displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity

AUTHOR: Armerding Dieter (Reprint); Fuhlbrigge Robert C; Kieffer J David; Kupper Thomas S

AUTHOR ADDRESS: Donaustrasse 73, A-3421, Hoefflein an der Donau, Austria**
Austria

JOURNAL: International Archives of Allergy and Immunology 126 (1): p78-90
September, 2001 2001

MEDIUM: print

ISSN: 1018-2438

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Skin-homing T cells are defined by the expression of the

cutaneous lymphocyte-associated antigen (CLA) which enables the cells to selectively bind to vascular endothelial E-selectin close to sites of cutaneous inflammation, an initial step in the effective extravasation from blood into the inflamed tissue. Essentially all CLA on T cells decorates the backbone of the P-selectin glycoprotein ligand-1 (PSGL-1). In this study we show that human peripheral blood B cells (PBBC) and tonsillar B cells (TBC) do not display PSGL-1 in fluorescence-activated cell sorter analysis using different murine monoclonal antibodies and polyclonal rabbit anti-PSGL-1 antiserum. A significant population of TBC, however, expresses a HECA-452-reactive epitope. These cells represent nonactivated IgM+/IgG- mature B lymphocytes. Up to 50% of the TBC in a given preparation strongly bind to E- and up to 79% to P-selectin. The shear stress resistance in a parallel-plate flow chamber system was high. Neuraminidase treatment of TBC totally and O-sialoglycoprotein endopeptidase partially diminished HECA-452 reactivity and reduced E- but not P-selectin ligand activities. Mocarhagin had no effect in the assays. The data suggest a different ligand for P-selectin and a distinct glycoprotein carrier for the E-selectin ligand as compared to T cells or other leukocytes. Adhesion to P-selectin, however, still required sulfation of the ligand for function. Western blots of TBC cell lysates detected a >240-kD HECA-452-reactive material that was resistant to reducing ***conditions***. Anti- ***PSGL*** -1 did not reveal immunoreactive material in these cell lysates. B cell activation did neither significantly change HECA positivity nor induce PSGL-1 expression. Cultured, activated TBC, however, maintained expression of the integrin alpha4beta7. Human peripheral blood B cells had similar cell surface characteristics to TBC. Our observations suggest that several adhesion molecules may be involved in B cell homing which include CLA, the P-selectin ligand, and structures such as alpha4beta7.

11/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013273769 BIOSIS NO.: 200100445608

Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G

AUTHOR: Gardiner Elizabeth E; De Luca Mariagrazia; McNally Tracy; Michelson Alan D; Andrews Robert K; Berndt Michael C (Reprint)

AUTHOR ADDRESS: Baker Medical Research Institute, St Kilda Rd, Central, Melbourne, VIC, Australia**Australia

JOURNAL: Blood 98 (5): p1440-1447 September 1, 2001 2001

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: In the inflammatory response, leukocyte rolling before adhesion and transmigration through the blood vessel wall is mediated by specific cell surface adhesion receptors. Neutrophil rolling involves the interaction of P-selectin expressed on activated endothelium and its counter-receptor on neutrophils, P-selectin glycoprotein ligand-1 (PSGL-1). Here, it is reported that P-selectin binding to neutrophils is lost under conditions that cause the release of proteinases from neutrophil primary granules. Treatment of neutrophils with the purified neutrophil granule proteinases, cathepsin G and elastase, rapidly abolished their capacity to bind P-selectin. This inactivation corresponded to loss of the N-terminal domain of PSGL-1, as assessed by Western blot analysis. A loss of intact PSGL-1 protein from the surfaces

of neutrophils after the induction of degranulation was also detected by Western blot analysis. Cathepsin G initially cleaved near the PSGL-1 N-terminus, whereas neutrophil elastase predominantly cleaved at a more C-terminal site within the protein mucin core. Consistent with this, cathepsin G cleaved a synthetic peptide based on the PSGL-1 N-terminus between Tyr-7/Leu-8. Under ***conditions*** producing neutrophil degranulation in incubations containing mixtures of platelets and neutrophils, the loss of PSGL-1, but not P-selectin, from platelet neutrophil lysates was ***detected***. Cathepsin G- or neutrophil elastase-mediated PSGL-1 proteolysis may constitute a potential autocrine mechanism for down-regulation of neutrophil adhesion to P-selectin.

11/7/4 (Item 4 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rights reserved.

0013257113 BIOSIS NO.: 200100428952

Expression and function of P-selectin glycoprotein ligand 1 (CD162) on human basophils

AUTHOR: Taylor Marcia L; Brummet Mary E; Hudson Sherry A; Miura Katsu; Bochner Bruce S (Reprint)

AUTHOR ADDRESS: Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bay View Circle, Baltimore, MD, 21224-6801, USA**USA

JOURNAL: Journal of Allergy and Clinical Immunology 106 (5): p918-924, November, 2000 2000

MEDIUM: print

ISSN: 0091-6749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Background: The endothelial cell adhesion molecule P-selectin may contribute to selective leukocyte migration in allergic diseases by binding to its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), on eosinophils and other leukocytes. Although expression of ***PSGL*** -1 on basophils has been detected in leukocyte typing workshops, its function on basophils has not been explored. Objective: We sought to characterize the expression and function of PSGL-1 on human basophils and a basophil-like cell line (KU812) and to compare these characteristics with those for PSGL-1 on eosinophils and neutrophils. Methods: Basophils, eosinophils, and neutrophils were enriched from peripheral blood by using density gradient centrifugation and immunomagnetic negative selection. KU812 cells were cultured by using standard techniques. Indirect immunofluorescence and flow cytometry were used to determine surface PSGL-1 expression under various conditions, and Western blotting was used to analyze the molecular forms of PSGL-1 on each cell type. Static adhesion assays were performed by using immobilized recombinant P-selectin and relevant blocking antibodies. Histamine release assays were done by using adherent and nonadherent basophils to determine whether adhesion by means of PSGL-1 altered basophil releasability. Results: The expression of PSGL-1 on basophils was similar to that on neutrophils but was approximately 30% less bright than levels on eosinophils. Levels on basophils were 10-fold higher than on KU812 cells. Basophil activation by means of IgE cross-linking resulted in reductions in surface expression of PSGL-1 and L-selectin, as well as increased CD11b expression. Western blot analysis of PSGL-1 revealed that the molecular weights of the bands for neutrophils and basophils were similar, whereas those for eosinophils were of greater molecular weights. Static adhesion assays demonstrated that basophils bound well to P-selectin, whereas KU812 cells bound poorly. Adhesion of

basophils to P-selectin was completely blocked by antibodies to either P-selectin or PSGL-1. Finally, adhesion to P-selectin did not alter the magnitude or kinetics of anti-IgE-induced histamine release. Conclusion: Expression of PSGL-1 on basophils is more similar to that on neutrophils than that on eosinophils. KU812 cells express much lower levels of this molecule but, like basophils and other cells, bind to P-selectin by means of PSGL-1. P-selectin expression at sites of allergic inflammation is likely to play an important role in human basophil recruitment, but adhesion by means of PSGL-1 does not alter IgE-dependent basophil histamine release.

11/7/5 (Item 1 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10823146 EMBASE No: 2000305388

Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro
Davenpeck K.L.; Brummet M.E.; Hudson S.A.; Mayer R.J.; Bochner B.S.
Dr. B.S. Bochner, Johns Hopkins Asthma/Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 United States
AUTHOR EMAIL: bbochner@welch.jhu.edu
Journal of Immunology (J. IMMUNOL.) (United States) 01 SEP 2000, 165/5 (2764-2772)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 39

P-selectin glycoprotein ligand-1 (PSGL-1), the primary ligand for P-selectin, is constitutively expressed on the surface of circulating leukocytes. The objective of this study was to examine the effect of leukocyte activation on PSGL-1 expression and PSGL-1-mediated leukocyte adhesion to P-selectin. PSGL-1 expression was examined via indirect immunofluorescence and flow cytometry before and after leukocyte stimulation with platelet activating factor (PAP) and PMA. Human neutrophils, monocytes, and eosinophils were all demonstrated to have significant surface expression of PSGL-1 at baseline, which decreased within minutes of exposure to PAP or PMA. ***PSGL*** -1 was ***detected*** in the supernatants of PAP-activated neutrophils by immunoprecipitation. Along with the expression data, this suggests removal of PSGL-1 from the cell surface. Soluble ***PSGL*** -1 was also ***detected*** in human bronchoalveolar lavage fluids. Down-regulation of ***PSGL*** -1 was inhibited by EDTA. However, inhibitors of L-selectin shedding and other sheddase inhibitors did not affect PSGL-1 release, suggesting that PSGL-1 may be shed by an as yet unidentified sheddase or removed by some other mechanism. Functionally, PSGL-1 down-regulation was associated with decreased neutrophil adhesion to immobilized P-selectin under both static and flow conditions, with the most profound effects seen under flow conditions. Together, these data indicate that PSGL-1 can be removed from the surface of activated leukocytes, and that this decrease in PSGL-1 expression has profound effects on leukocyte binding to P-selectin, especially under conditions of flow.

?

13/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0016086159 BIOSIS NO.: 200600431554
Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis
AUTHOR: Rivera-Nieves Jess (Reprint); Burcin Tracy L; Olson Timothy S; Morris Margaret A; McDuffie Marcia; Cominelli Fabio; Ley Klaus
AUTHOR ADDRESS: Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA**USA
AUTHOR E-MAIL ADDRESS: jr3u@virginia.edu
JOURNAL: Journal of Experimental Medicine 203 (4): p907-917 APR 17 2006
2006
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The Journal of Experimental Medicine L-selectin ligands might be relevant for inflammatory cell trafficking into the small intestine in a spontaneous model of chronic ileitis (i.e., SAMP1/YitFc mice). Immunoblockade of peripheral node addressin or mucosal addressin cell adhesion molecule 1 failed to ameliorate ileitis, whereas P-selectin glycoprotein ligand 1 (PSGL-1) neutralization attenuated both the adoptively transferred and spontaneous ***disease***. ***PSGL*** -1 was detected in venules of mesenteric lymph node and small intestine by immunohistochemistry and confirmed by real-time reverse transcription polymerase chain reaction and flow cytometry. In addition, reconstitution of wild-type mice with PSGL-1(-/-) bone marrow demonstrated that PSGL-1 messenger RNA and PSGL-1 protein expression remained on endothelium, localized within mesenteric lymph node and small intestine. Endothelial PSGL-1 bound P-selectin-IgG and its blockade or genetic deletion altered the recruitment of lymphocytes to the small intestine, as revealed by intravital microscopy and homing studies. Endothelial expression of PSGL-1 adds a new dimension to the various cellular interactions involved in small intestinal recruitment. Thus, the multiple roles of PSGL-1 may explain why targeting this single adhesion molecule results in attenuation of chronic murine ileitis, a disease previously resistant to antiadhesion molecule strategies.

13/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013257113 BIOSIS NO.: 200100428952
Expression and function of P-selectin glycoprotein ligand 1 (CD162) on human basophils
AUTHOR: Taylor Marcia L; Brummet Mary E; Hudson Sherry A; Miura Katsu; Bochner Bruce S (Reprint)
AUTHOR ADDRESS: Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bay View Circle, Baltimore, MD, 21224-6801, USA**USA
JOURNAL: Journal of Allergy and Clinical Immunology 106 (5): p918-924 November, 2000 2000
MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: The endothelial cell adhesion molecule P-selectin may contribute to selective leukocyte migration in allergic diseases by binding to its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), on eosinophils and other leukocytes. Although expression of ***PSGL*** -1 on basophils has been detected in leukocyte typing workshops, its function on basophils has not been explored. Objective: We sought to characterize the expression and function of PSGL-1 on human basophils and a basophil-like cell line (KU812) and to compare these characteristics with those for PSGL-1 on eosinophils and neutrophils. Methods: Basophils, eosinophils, and neutrophils were enriched from peripheral blood by using density gradient centrifugation and immunomagnetic negative selection. KU812 cells were cultured by using standard techniques. Indirect immunofluorescence and flow cytometry were used to determine surface PSGL-1 expression under various conditions, and Western blotting was used to analyze the molecular forms of PSGL-1 on each cell type. Static adhesion assays were performed by using immobilized recombinant P-selectin and relevant blocking antibodies. Histamine release assays were done by using adherent and nonadherent basophils to determine whether adhesion by means of PSGL-1 altered basophil releasability. Results: The expression of PSGL-1 on basophils was similar to that on neutrophils but was approximately 30% less bright than levels on eosinophils. Levels on basophils were 10-fold higher than on KU812 cells. Basophil activation by means of IgE cross-linking resulted in reductions in surface expression of PSGL-1 and L-selectin, as well as increased CD11b expression. Western blot analysis of PSGL-1 revealed that the molecular weights of the bands for neutrophils and basophils were similar, whereas those for eosinophils were of greater molecular weights. Static adhesion assays demonstrated that basophils bound well to P-selectin, whereas KU812 cells bound poorly. Adhesion of basophils to P-selectin was completely blocked by antibodies to either P-selectin or PSGL-1. Finally, adhesion to P-selectin did not alter the magnitude or kinetics of anti-IgE-induced histamine release. Conclusion: Expression of PSGL-1 on basophils is more similar to that on neutrophils than that on eosinophils. KU812 cells express much lower levels of this molecule but, like basophils and other cells, bind to P-selectin by means of PSGL-1. P-selectin expression at sites of allergic inflammation is likely to play an important role in human basophil recruitment, but adhesion by means of PSGL-1 does not alter IgE-dependent basophil histamine release.

?

? s (psgl?) and (diagnos? or detect?) (20n) (diseas? or disorder?)

Processing

Processing

1861 PSGL?
5873949 DIAGNOS?
3340223 DETECT?
9871459 DISEAS?
2375630 DISORDER?
1744220 (DIAGNOS? OR DETECT?) (20N) (DISEAS? OR DISORDER?)
S14 23 (PSGL?) AND (DIAGNOS? OR DETECT?) (20N) (DISEAS? OR
DISORDER?)

? rd s14

S15 19 RD S14 (unique items)

? t s15/3/all

15/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0016086159 BIOSIS NO.: 200600431554

Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic
murine ileitis

AUTHOR: Rivera-Nieves Jess (Reprint); Burcin Tracy L; Olson Timothy S;
Morris Margaret A; McDuffie Marcia; Cominelli Fabio; Ley Klaus

AUTHOR ADDRESS: Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence,
Charlottesville, VA 22908 USA**USA

AUTHOR E-MAIL ADDRESS: jr3u@virginia.edu

JOURNAL: Journal of Experimental Medicine 203 (4): p907-917 APR 17 2006
2006

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

15/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015458540 BIOSIS NO.: 200510153040

Influence of the novel M62I polymorphism in PSGL-1 gene on
susceptibility and progression of multiple sclerosis

AUTHOR: Galimberti Daniela (Reprint); Fenoglio Chiara; De Riz Milena;
Ronconi Marco; Piccio Laura; Comi Cristoforo; Venturelli Eliana; Brighina
Erika; Scalabrini Diego; Monaco Francesco; Constantin Gabriela; Bresolin
Nereo; Scarpini Elio

JOURNAL: Neurology 64 (6, Suppl. 1): pA86 MAR 22 05 2005

CONFERENCE/MEETING: 57th Annual Meeting of the
American-Academy-of-Neurology Miami Beach, FL, USA April 09 -19, 2005;
20050409

SPONSOR: Amer Acad Neurol

ISSN: 0028-3878

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Citation

LANGUAGE: English

15/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015348514 BIOSIS NO.: 200510043014

Molecular determinants of the prothrombogenic phenotype assumed by inflamed colonic venules

AUTHOR: Mori Mikiji; Salter James W; Vowinkel Thorsten; Krieglstein Christian F; Stokes Karen Y; Granger D Neil (Reprint)

AUTHOR ADDRESS: Louisiana State Univ, Hlth Sci Ctr, Dept Cellular and Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA**USA

AUTHOR E-MAIL ADDRESS: dgrang@lsuhsc.edu

JOURNAL: American Journal of Physiology - Gastrointestinal and Liver Physiology 288 (5): pG920-G926 MAY 05 2005

ISSN: 0193-1857

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

15/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015105509 BIOSIS NO.: 200500012574

The emerging value of P-selectin as a disease marker

AUTHOR: Kappelmayer Janos (Reprint); Nagy Bela Jr; Misztai-Blasius Kornel; Hevessy Zsuzsa; Setiadi Hendra

AUTHOR ADDRESS: Dept Clin Biochem and Mol PatholMed and Hlth Sci Ctr, Debrecen Univ Med, Nagyerdei Krt 98, H-4012, Debrecen, Hungary**Hungary

AUTHOR E-MAIL ADDRESS: kappelmayer@jaguar.dote.hu

JOURNAL: Clinical Chemistry and Laboratory Medicine 42 (5): p475-486 2004 2004

MEDIUM: print

ISSN: 1434-6621

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

15/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015019781 BIOSIS NO.: 200400390570

Differential expression of cutaneous lymphocyte antigen in lymphomatoid papulosis and lymphomas is a potential marker for diagnosis and tumor progression

AUTHOR: Kadin M E (Reprint); Nacem H; Kieffer D; King S; Severy P; Pinkus J L; Pinkus G S; Kupper T S

AUTHOR ADDRESS: Sch Med, Harvard Univ, Boston, MA, 02115, USA**USA

JOURNAL: Journal of Investigative Dermatology 122 (3): pA30 March 2004 2004

MEDIUM: print

CONFERENCE/MEETING: The 65th Annual Meeting of the Society for Investigative Dermatology Providence, Rhode Island, USA April 28-May 01, 2004; 20040428

SPONSOR: Society for Investigative Dermatology

ISSN: 0022-202X (ISSN print)

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

15/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013542781 BIOSIS NO.: 200200136292

Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias

AUTHOR: Kappelmayer Janos (Reprint); Kiss Attila; Karaszi Eva; Veszpremi Aniko; Jako Janos; Kiss Csongor

AUTHOR ADDRESS: Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Sciences Centre, University of Debrecen, Debrecen, H-4012, Hungary**Hungary

JOURNAL: British Journal of Haematology 115 (4): p903-909 December, 2001 2001

MEDIUM: print

ISSN: 0007-1048

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

15/3/7 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13615491 EMBASE No: 2006034774

Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement

Florena A.M.; Tripodo C.; Porcasi R.; Ingrao S.; Fadda M.R.; De Cantis S.; Iannitto E.; Franco V.

Prof. A.M. Florena, Istituto di Anatomia ed Istologia Patologica, Universita degli Studi, Via del Vespro 129, 90127 Palermo Italy

AUTHOR EMAIL: amflorena@unipa.it

Leukemia and Lymphoma (LEUK. LYMPHOMA) (United Kingdom) 2006, 47/1 (49-57)

CODEN: LELYE ISSN: 1042-8194

PUBLISHER ITEM IDENTIFIER: M4087341027776

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 34

15/3/8 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

14495001 PMID: 13679485

Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients.

Ashman Neil; Macey Marion G; Fan Stanley L; Azam Urooj; Yaqoob Muhammad M
Department of Renal Medicine and Transplantation, The Royal London Hospital, Whitechapel, London E1 1BB, UK.

Nephrology, dialysis, transplantation - official publication of the European Dialysis and Transplant Association - European Renal Association (England) Oct 2003, 18 (10) p2088-96, ISSN 0931-0509--Print

Journal Code: 8706402

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

15/3/9 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142353888 CA: 142(19)353888h PATENT

Antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther; Hagay, Yocheved; Ben-levy, Rachel; Nisgav, Yael; Kanfi, Yariv

LOCATION: Israel

PATENT: U.S. Pat. Appl. Publ. ; US 20050069955 A1 DATE: 20050331

APPLICATION: US 2004880922 (20040630) *US 2003PV484061 (20030630)

PAGES: 74 pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 435007100; G01N-033/53A; C07K-016/18B

15/3/10 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142349113 CA: 142(19)349113j (CORRECTION OF 142(9)148820p) PATENT

Anti-PSGL-1 antibodies, and diagnostic and therapeutic use

INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel; Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton, Esther; Kanfi, Yariv; Ben-Levy, Rachel

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200505455 A2 DATE: 20050120

APPLICATION: WO 2004US21099 (20040630) *US 2003610840 (20030630)

PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

15/3/11 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142259973 CA: 142(14)259973k PATENT

Antibodies specific to human interleukin-22 for diagnosis and treatment of inflammatory and immune or autoimmune diseases

INVENTOR(AUTHOR): Li, Jing; Tan, Xiang-yang; Tomkinson, Kathleen N.; Pittman, Debra D.; Veldman, Geertruida M.; Fouser, Lynette

LOCATION: USA

ASSIGNEE: Genetics Institute, LLC

PATENT: U.S. Pat. Appl. Publ. ; US 20050042220 A1 DATE: 20050224

APPLICATION: US 2004873972 (20040622) *US 2001PV270823 (20010223) *US 2001PV281353 (20010403) *US 200284298 (20020225) *US 2003PV480652 (20030623)

PAGES: 59 pp., Cont.-in-part of U.S. Ser. No. 84,298. CODEN: USXXCO

LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 424145100; C07K-016/24A; A61K-039/395B

15/3/12 (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142196523 CA: 142(11)196523r PATENT
Antibodies bind to sulfated epitopes involving cell rolling, metastasis, inflammation, viral entry and autoimmune disease for diagnosis, prognosis and therapy
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther; Hagay, Yocheved; Ben-Levy, Rachel; Nisgav, Yael; Szrajber, Tali; Kanfi, Yariv
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200510153 A2 DATE: 20050203
APPLICATION: WO 2004US21002 (20040630) *US 2003611238 (20030630)
PAGES: 134 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

15/3/13 (Item 5 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142073419 CA: 142(5)73419d PATENT
Method for identification of TR1 regulator lymphocytes by the presence and the expression of specific molecules, and diagnostic and therapeutic applications
INVENTOR(AUTHOR): Groux, Herve
LOCATION: Fr.
ASSIGNEE: Txcell
PATENT: France Demande ; FR 2856700 A1 DATE: 20041231
APPLICATION: FR 20037601 (20030624)
PAGES: 89 pp. CODEN: FRXXBL LANGUAGE: French
PATENT CLASSIFICATIONS:
CLASS: C12Q-001/68A; G01N-033/68B; C12N-005/08B; A61K-035/14B; A61P-029/00B; A61P-037/02B

15/3/14 (Item 6 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

141365149 CA: 141(22)365149k PATENT
Anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Mar-Chaim, Hagit Hoch
LOCATION: Israel

PATENT: U.S. Pat. Appl. Publ. ; US 20040208877 A1 DATE: 20041021
APPLICATION: US 611588 (20030630) *US PV393491 (20020701)
PAGES: 49 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424146100; C12Q-001/68A; A61K-039/395B; C07K-016/40B

15/3/15 (Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for
diagnosis, prognosis and treatment of cancer, inflammation, infection,
autoimmune disease, metastasis and leukemia
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;
Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108
APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

15/3/16 (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140092576 CA: 140(7)92576c PATENT
Antibodies specific to epitopes involving cell rolling, metastasis and
inflammation for diagnosis and treatment of cancer, metastasis, leukemia,
autoimmune disease and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101
APPLICATION: US 32423 (20011231) *US PV258948 (20001229)
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B;
C07K-014/16B; C07K-007/08B; C07K-007/06B

15/3/17 (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140075946 CA: 140(6)75946f PATENT
Multimers of peptide epitopes containing sulfated moieties, antibodies to

such epitopes, and diagnostic and therapeutic uses thereof
INVENTOR(AUTHOR): Levanon, Avigdor; Hagay, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Lazarovits, Janette
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040001839 A1 DATE: 20040101
APPLICATION: US 29988 (20011231) *US PV258948 (20001229)
PAGES: 149 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424178100; A61K-039/395A; C07K-014/46B

15/3/18 (Item 10 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

137108286 CA: 137(8)108286j PATENT
Antibodies and fragments against epitopes present on cancer, metastatic
or leukemia cells and platelets for diagnosis and therapy of tumor,
metastasis, leukemia, autoimmune disease, and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagai, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Kooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: USA
ASSIGNEE: Bio-Technology General Corp.
PATENT: PCT International ; WO 200253700 A2 DATE: 20020711
APPLICATION: WO 2001US49442 (20011231) *US 751181 (20001229) *US PV258948
(20001229)
PAGES: 310 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

15/3/19 (Item 11 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

136000640 CA: 136(1)640k PATENT
Methods for diagnosing and treating hemostatic disorders by modulating
P-selectin activity
INVENTOR(AUTHOR): Wagner, Denisa D.; Andre, Patrick; Hartwell, Daqing W.;
Hrachovinova, Ingrid
LOCATION: USA
ASSIGNEE: The Center for Blood Research
PATENT: PCT International ; WO 200189564 A2 DATE: 20011129
APPLICATION: WO 2001US16021 (20010517) *US PV205734 (20000519)
PAGES: 93 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A; A61K-048/00B; A61K-038/17B; A61K-035/14B;
A61P-007/00B; A61P-009/00B; A61P-035/00B; G01N-033/50B; G01N-033/86B;
G01N-033/68B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;

CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
? t s15/7/4

15/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015105509 BIOSIS NO.: 200500012574
The emerging value of P-selectin as a disease marker
AUTHOR: Kappelmayer Janos (Reprint); Nagy Bela Jr; Miszti-Blasius Kornel;
Hevessy Zsuzsa; Setiadi Hendra
AUTHOR ADDRESS: Dept Clin Biochem and Mol PatholMed and Hlth Sci Ctr,
Debrecen Univ Med, Nagyerdei Krt 98, H-4012, Debrecen, Hungary**Hungary
AUTHOR E-MAIL ADDRESS: kappelmayer@jaguar.dote.hu
JOURNAL: Clinical Chemistry and Laboratory Medicine 42 (5): p475-486 2004
2004
MEDIUM: print
ISSN: 1434-6621
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Activated platelets are key components in many arterial disorders. P-selectin is an activation-dependent platelet receptor, which is also identified in endothelial cells. Together with E- and L-selectin it constitutes the selectin family. These transmembrane proteins have continued to attract great interest as they support rapid and reversible cell adhesion in flow systems and thus play an essential role in multicellular interactions during thrombosis and inflammation. Similarly to other lectins, selectins bind to different glycoconjugates with varying affinities. Protein ligands, equipped with the appropriate carbohydrate and sulfate moieties for P-selectin binding, have been identified in normal peripheral blood leukocytes and several non-hematopoietic organs, as well as on cancer cells. For diagnostic purposes, P-selectin can readily be detected on the platelet surface by flow cytometry and by ELISA as a soluble ligand in the plasma. Along with other markers, these data can be used in the assessment of platelet